Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX® (neratinib) within Europe and part of Africa.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2019.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were...
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) to commercialize NERLYNX® (neratinib) in...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 12, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,688...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018.
Investors in Puma Biotechnology Inc saw new options become available today, for the April 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new April 12th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 14, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.
Investors in Puma Biotechnology Inc saw new options become available today, for the March 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new March 29th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that the class action lawsuit, Hsu vs.
Investors in Puma Biotechnology Inc saw new options begin trading today, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc.
Investors in Puma Biotechnology Inc saw new options become available this week, for the February 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new February 8th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Investors in Puma Biotechnology Inc saw new options become available today, for the February 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new February 22nd contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 30, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 10,750...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company's lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Maximo F.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Maximo F.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma's drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from the Company's Phase III ExteNET Trial of neratinib for early stage...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 2, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,875...
Investors in Puma Biotechnology Inc saw new options become available today, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BERY, DLTH, DNB, ETSY, LND, MOS Downgrades: CIZN, CVV, FCX, LIND, OAS, PACW, PTVCB, STN, SYF, WAFD Initiations: CSSE, PBYI, PVG, SMPL, TRMT Read on to get TheStreet Quant Ratings' detailed report:
Investors in Puma Biotechnology Inc saw new options begin trading today, for the December 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new December 28th contracts and identified one put and one call contract of particular interest.
